Welcome to our dedicated page for SRX Global SEC filings (Ticker: SRXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRx Health Solutions, Inc. has closed its previously announced share exchange transaction with EMJ Crypto Technologies Inc. and CCC Crypto Corp., acquiring 100% of their equity interests and a 100% ownership interest in the defined IP Asset. At closing, the company issued an aggregate 268,346,659 shares of common stock, 117,268,196 exchangeable shares of ExchangeCo (on a one-for-one basis into common stock), and pre-funded warrants to purchase 44,368,530 shares of common stock, all registered on an effective Form S-4.
Immediately after closing, the company changed its legal name from SRx Health Solutions, Inc. to SRX Global Inc., while its stock continues to trade on the NYSE American under the ticker SRXH and will use the existing name for up to 10 business days. A related press release describes the launch of an AI-driven capital allocation platform centered on investments in high-conviction operating companies and assets.
SRx Health Solutions, Inc. registered up to 2,506,893,959 shares of Common Stock for resale by Keystone Capital Partners, LLC. This prospectus supplement to the Prospectus covers resale of those shares by the Selling Stockholder and attaches related Form 8-Ks filed March 18, April 17 and April 22, 2026. The Company states it will not receive proceeds from resale transactions by Keystone, though it may receive proceeds if it itself sells shares to Keystone under the ELOC Purchase Agreement. The supplement also describes a March 16, 2026 private placement: issuance of 5,660 Series B Preferred Shares and 22,237,666 Warrants for aggregate proceeds of approximately $4.528 million. Warrant exercise and preferred conversion mechanics, anti-dilution protections, a 4.99% beneficial ownership limit and extensive Triggering Event provisions are included.
SRx Health Solutions, Inc. updates a prospectus supplement registering the resale by selling stockholders of up to 187,544,974 shares of Common Stock for resale by the named selling stockholders, subject to beneficial ownership and exchange limitations. The resale pool aggregates multiple classes of underlying securities, including warrants, convertible preferred stock conversion rights, exchangeable Canadian shares, private placement shares, service provider shares and shares issued in a share exchange. The Company notes a closing market price of $0.1300 per share on June 4, 2026. The prospectus supplement incorporates recent 8-Ks dated March 18, 2026, April 17, 2026, and April 22, 2026 and discloses a separate March 16, 2026 private placement that issued 5,660 Series B Preferred Shares and 22,237,666 warrants for approximately $4.528 million.
SRx Health Solutions Inc. reports its first full quarter focused on premium pet products after exiting its Canadian healthcare business. For the three months ended March 31, 2026, net sales from continuing operations were $3.4 million, entirely from Digital, International, and Brick & Mortar pet channels, and the company recorded a net loss from continuing operations of $6.4 million (basic and diluted loss per share of $0.02).
Cash and cash equivalents rose to $20.5 million as of March 31, 2026 from $1.3 million at September 30, 2025, driven by equity financing, including common stock issued under a $1.0 billion equity line of credit and new Series B preferred stock and warrants. A $22.6 million ELOC Commitment Note is the company’s principal debt.
SRx also holds $8.3 million of crypto assets and actively trades derivatives and equity securities, introducing additional volatility. Management states that recent financings and cost actions support a going concern view, while an all‑stock $55 million EMJX transaction is expected to add digital-asset-related businesses.
SRx Health Solutions discloses a proposed all-stock acquisition to buy EMJ Crypto Technologies, CCC Crypto Corp. and related intellectual property for an aggregate purchase price of approximately $55 million under a Share Exchange and Asset Transfer Agreement dated December 16, 2025 (amended March 11, 2026). The prospectus covers up to 550,000,000 SRXH common shares issuable as consideration, including exchangeable shares and pre-funded warrants. The Board recommended the Transaction and certain stockholders holding 14,180,156 shares (representing 51.15%) delivered written consents approving the proposals; no proxy solicitation will occur. The parties expect the closing in Q2 2026, subject to customary conditions and NYSE American and other regulatory approvals.
SRx Health Solutions, Inc. proposes an all‑stock acquisition of EMJ Crypto Technologies Inc., CCC Crypto Corp. and related IP for an aggregate purchase price of approximately $55.0 million. The transaction contemplates issuing up to 550,000,000 SRXH common shares (including exchangeable shares and pre‑funded warrants) and could increase outstanding common shares by 20% or more. The Transfer Agreement was approved by written consent representing 51.15% of outstanding voting stock and includes customary closing conditions, regulatory approvals (including NYSE American listing), a fairness opinion from Hyperion Capital Inc., and termination rights. The parties expect accounting treatment as an asset acquisition under ASC 805 and anticipate a closing in Q2 2026, subject to satisfaction or waiver of conditions.
SRx Health Solutions, Inc. announced that its wholly owned subsidiary, Halo, Purely for Pets, Inc., has invested more than 10% of the company’s aggregate treasury assets in Astro Investment XVII, an affiliate of Astro Capital structured as a special purpose vehicle.
The company and EMJ Crypto Technologies highlighted that this represents an investment of greater than 10% of their investable capital, targeting opportunities at the intersection of artificial intelligence and space-related businesses. The disclosure also notes that SRx has filed a Registration Statement on Form S-4 covering common stock to be issued in its previously announced merger with EMJX, with an information statement/prospectus to be sent to stockholders after effectiveness.
SRx Health Solutions, Inc. released a shareholder letter from EMJ Crypto Technologies founder Eric M. Jackson updating on their proposed merger and EMJX’s recent performance. EMJX deployed $18 million into its second-generation digital-asset treasury hedging strategy, earning a 5.69% return in March 2026 versus a 4.98% decline in the S&P 500, a 10.67% outperformance. Through mid-April, EMJX reports approximate gains of 3.5% in its hedging pool and 8% in long treasury holdings. The Company filed a Form S-4 registration statement for the merger, after which a regulatory review is expected before the transaction can close.